Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc2214773 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Respiratory Syncytial Virus: A WAidid Consensus Document on New Preventive Options.
Vaccines (Basel)
November 2024
Pediatric Clinic, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.
Respiratory syncytial virus (RSV) is a leading cause of respiratory infections, particularly affecting young infants, older adults, and individuals with comorbidities. : This document, developed as a consensus by an international group of experts affiliated with the World Association of Infectious Diseases and Immunological Disorders (WAidid), focuses on recent advancements in RSV prevention, highlighting the introduction of monoclonal antibodies (mAbs) and vaccines. : Historically, RSV treatment options were limited to supportive care and the monoclonal antibody palivizumab, which required multiple doses.
View Article and Find Full Text PDFRSV immunization uptake among infants and pregnant persons - Wisconsin, October 1, 2023-March 31, 2024.
Vaccine
January 2025
Wisconsin Division of Public Health, 1 West Wilson St., Madison, WI, United States.
Respiratory syncytial virus (RSV) is the leading cause of hospitalizations among infants in the United States. New strategies to prevent RSV among infants and high-risk young children include the maternal RSVpreF vaccine (Abrysvo, Pfizer Inc.) and nirsevimab (Beyfortus, Sanofi and AstraZeneca), a long-acting monoclonal antibody.
View Article and Find Full Text PDFA framework for monitoring RSV prevention product effectiveness in the United States.
Vaccine
January 2025
National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
During 2023, the Centers for Disease Control and Prevention (CDC) recommended the first respiratory syncytial virus (RSV) immunizations intended for widespread use in the United States to prevent severe RSV illness in infants and older adults. CDC, in collaboration with federal, public health, and academic partners, is conducting evaluations of real-world effectiveness of recommended RSV immunization products in the United States. Similar frameworks for evaluation are being applied to RSV vaccines and nirsevimab, a long-acting preventative monoclonal antibody, to estimate product effectiveness.
View Article and Find Full Text PDFEvolving Strategies for Respiratory Syncytial Virus (RSV): A Review Article of Preventive Agents and Vaccines for RSV.
Ann Pharmacother
January 2025
ForHealth Consulting, UMass Chan Medical School, Shrewsbury, MA, USA.
Objective: The objective was to describe the pharmacology, efficacy, safety, and recommendations for the use of newly approved preventive agents and vaccines for respiratory syncytial virus (RSV) and discuss their uptake during the 2023 to 2024 RSV season.
Data Sources: A literature search of PubMed was performed (January 2020 to February 2024) with the search terms RSV vaccine, preventive antibody, and RSV prevention. Utilization data were collected from TriNetX using the US Collaborative Network (May 2024) using the terms palivizumab, nirsevimab, and RSV prefusion F protein.
A phase I, randomized, placebo-controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults.
Clin Transl Sci
January 2025
Clinical Pharmacology, R&D China, AstraZeneca, Shanghai, China.
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection (LRTI) in infants worldwide. Nirsevimab, an extended half-life monoclonal antibody against RSV, is approved in China for the prevention of RSV lower respiratory tract disease in infants; however, global nirsevimab trials did not enroll Chinese infants. To inform the investigation of nirsevimab for the prevention of RSV LRTI in Chinese infants, this Phase I, randomized, placebo-controlled trial evaluated the pharmacokinetics (PK) and safety of nirsevimab in healthy Chinese adults.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!